TOKYO and NEW YORK, Feb. 11, 2020 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today results of the final overall survival (OS) analysis from the Phase 3...
Investigation underway into unexpected and inconsistent findings that may have negatively impacted results reported in TRILOGY 1 Announces plans to seek FDA guidance prior to unblinding TRILOGY 2 data, which is expected to delay reporting of TRILOGY 2 topline results...
Oxurion NV (OXUR), a biopharmaceutical company developing next generation therapies designed to treat patients with diabetic eye disease, today announces that further positive topline data from a Phase 1 study with THR-687, a novel, potent, pan-RGD integrin antagonist...
/EIN News/ — SAN CARLOS, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) — Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced the initiation of a phase...
RRP is a rare, potentially fatal orphan disease caused by Human Papillomavirus (HPV) 6 and 11 Inovio’s DNA medicine pipeline includes 15 clinical programs focused on HPV-associated diseases, cancer, and infectious diseases, including the novel coronavirus...
INDIANAPOLIS, Feb. 10, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that the analysis performed by Washington University School of Medicine in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study showed that solanezumab...
Email
Text